- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05297552
A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer
February 18, 2024 updated by: RemeGen Co., Ltd.
An Open-label, Single-arm, Multi-center, Phase II Study to Evaluate the Efficacy and Safety of RC48-ADC Combined With JS001 in Perioperative Treatment of Muscle-Invasive Bladder Cancer
This study will evaluate the efficacy and safety of intravenous RC48-ADC combined with JS001 in perioperative treatment of muscle-invasive bladder cancer.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Na Su
- Phone Number: +8610-58075763
- Email: na.su@remegen.cn
Study Contact Backup
- Name: Jianmin Fang
- Phone Number: +8610-58075763
- Email: jianminfang@hotmail.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Recruiting
- Beijing Cancer Hospital
-
Contact:
- Yong Yang
-
Beijing, Beijing, China
- Recruiting
- Peking University First Hospital
-
Contact:
- Zhisong He
-
Beijing, Beijing, China, 100078
- Recruiting
- Beijing Cancer Hospital
-
Contact:
- Jun Guo
-
Principal Investigator:
- Jun Guo, Ph.D
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Voluntary agreement to provide written informed consent.
- Male or female, Age ≥ 18 years.
- Predicted survival ≥ 12 weeks.
- Histologically confirmed diagnosis of muscle invasive bladder cancer (MIBC) .Naive of antitumor systematic treatment or radiotherapy.
- Have clinically non-metastatic bladder cancer (cT2-T4a, N0-1, M0) determined by imaging.
- Be deemed eligible for Radical Cystectomy (RC) + Pelvic Lymph Node Dissection (PLND).
- HER2 expressing (i.e. IHC 1+ 2+ or 3+) as confirmed by the local lab.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Adequate organ function, evidenced by the following laboratory results within 7 days prior to the study treatment.
- Male and female participants are eligible to participate if they agree to the contraception use as per study protocol.
- Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.
Exclusion Criteria:
- Has received other antitumor therapy before planned start of trial treatment.
- History of major surgery within 4 weeks of planned start of trial treatment.
- Diagnosed with HBsAg, HBcAb positive and HBV DNA copy positive, or HCVAb positive, or HIVAb positive.
- Has received a live virus vaccine within 4 weeks of planned start of trial treatment.
- NYHA Class III heart failure.
- Suffering from active infection requiring systemic treatment.
- Uncontrolled hypertension, diabetes, Interstitial lung Disease, or COPD;
- Treated with systemic treatment (e.g. immunomodulators, corticosteroids or immunosuppressants) for the autoimmune disease within 2 years prior to the study treatment.
- History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with a similar curative outcome as those mentioned above.
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- Pregnancy or lactation.
- Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RC48-ADC + JS001
Participants received 6 preoperative cycles of RC48-ADC PLUS JS001, followed by surgery, followed by up to 20 cycles of postoperative JS001.
|
Drug: RC48-ADC 2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
Drug: JS001 3.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathologic Complete Response (pCR) Rate
Time Frame: Up to approximately 16 Weeks (Time of surgery)
|
pCR rate is defined as the percentage of participants having pCR.
pCR is defined as absence of viable tumor (pT0pT0N0) in examined tissue from RC and PLND.
|
Up to approximately 16 Weeks (Time of surgery)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Pathologic Response
Time Frame: Up to approximately 16 Weeks (Time of surgery)
|
No residual tumor (ypT0N0) and partial response (ypTis-1N0) in surgical specimen.
|
Up to approximately 16 Weeks (Time of surgery)
|
1-year Disease Free Survival Rate
Time Frame: From approximately 16 Weeks up to approximately 12 Months.
|
The percentage of participants disease free on 1 year after surgery.
|
From approximately 16 Weeks up to approximately 12 Months.
|
Objective Response Rate (ORR)
Time Frame: Up to approximately 12 Weeks.
|
Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR)
|
Up to approximately 12 Weeks.
|
Overall Survival (OS)
Time Frame: Up to approximately 60 Months.
|
Overall survival is defined as the time from enrollment to death due to any cause.
|
Up to approximately 60 Months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jun Guo, Ph.D, Peking University Cancer Hospital & Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 26, 2022
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
February 28, 2025
Study Registration Dates
First Submitted
March 17, 2022
First Submitted That Met QC Criteria
March 17, 2022
First Posted (Actual)
March 28, 2022
Study Record Updates
Last Update Posted (Actual)
February 20, 2024
Last Update Submitted That Met QC Criteria
February 18, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC48-C017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscle Invasive Bladder Carcinoma
-
Fox Chase Cancer CenterJanssen PharmaceuticalsNot yet recruitingUrothelial Carcinoma | Non-Muscle Invasive Bladder Urothelial Carcinoma | Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
University of Roma La SapienzaNot yet recruitingNon-muscle-invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
-
Aura BiosciencesRecruitingMuscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder CancerUnited States
-
National Cancer Institute (NCI)Not yet recruitingNon-Muscle Invasive Bladder Urothelial Carcinoma | Recurrent Non-Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
Nucleix Ltd.CompletedNon Muscle Invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
AstraZenecaHospital Israelita Albert EinsteinRecruitingUrothelial Carcinoma | Muscle-invasive Bladder Cancer | Non Muscle Invasive Bladder CancerBrazil
-
University of VirginiaAmerican Cancer Society, Inc.; Integrated Translational Health Research Institute...RecruitingBladder Cancer | Muscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder CancerUnited States
-
IRCCS San RaffaeleRecruitingBladder Cancer | Bladder Disease | Bladder Cancer Recurrent | Bladder Urothelial Carcinoma | Non Muscle Invasive Bladder Cancer | Bladder Neoplasm | Non-Muscle Invasive Bladder Urothelial Carcinoma | Non-Muscle Invasive Bladder Neoplasms | Bladder Cancer Stage I, With Cancer in Situ | Bladder Urothelial... and other conditionsItaly
-
enGene, Inc.RecruitingSuperficial Bladder Cancer | Non-muscle Invasive Bladder Cancer With Carcinoma in SituUnited States
-
CG Oncology, Inc.RecruitingBladder Cancer | Urothelial Carcinoma | Urologic Cancer | Non Muscle Invasive Bladder CancerUnited States
Clinical Trials on RC48-ADC
-
Cancer Institute and Hospital, Chinese Academy...RecruitingMetastatic Breast CancerChina
-
RemeGen Co., Ltd.Completed
-
RemeGen Co., Ltd.Completed
-
Tianjin Medical University Cancer Institute and...Chongqing University Cancer Hospital; Xiangya Hospital of Central South University and other collaboratorsNot yet recruitingNeoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
-
Chinese PLA General HospitalRecruitingAdvanced Gastroesophageal AdenocarcinomaChina
-
RemeGen Co., Ltd.Completed
-
Peking Union Medical College HospitalRecruitingSalivary Gland TumorsChina
-
RemeGen Co., Ltd.Not yet recruitingNon-small Cell Lung CancerChina